BiotechTube
Medice

Medice

Iserlohn, Germany· Est.
medice.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Medice is a well-established, privately-held German pharmaceutical company with over 75 years of history, transitioning from a traditional drug developer to an integrated 'Health Family' provider. Its core business is the development, manufacturing, and international commercialization of small molecule therapeutics, primarily in ADHD, nephrology, urology, and self-medication. The company is strategically expanding beyond pure pharmaceuticals into multimodal healthcare, including digital health applications (DiGA) and nutritional concepts, aiming to create comprehensive treatment ecosystems. With over 1,000 employees and a strong international distribution network, Medice is on a long-term growth trajectory.

ADHDNephrologyUrologySelf-Medication

Technology Platform

Integrated 'Health Family' model combining small molecule pharmaceuticals with digital health applications (DiGAs) and indication-based nutritional concepts to create multimodal treatment ecosystems.

Opportunities

The growing global ADHD market and the nascent but reimbursed digital therapeutics sector in Germany provide significant expansion opportunities.
An aging population and rising chronic disease rates drive sustained demand in nephrology and urology, where integrated nutritional concepts can differentiate its offerings.
The company's international distribution network allows for the scalable export of its multimodal treatment models.

Risk Factors

Revenue dependence on a few therapeutic areas exposes the company to generic competition and regulatory shifts.
The digital health strategy faces adoption and reimbursement risks beyond Germany.
As a private company, access to large-scale capital for major acquisitions or R&D may be limited compared to public competitors.

Competitive Landscape

Medice competes with large global pharmaceutical companies (e.g., Takeda, Novartis) in ADHD and nephrology, as well as with generic manufacturers. In digital health for ADHD, it is a first-mover in the German DiGA market, competing against pure-play digital therapy startups. Its integrated 'pharma-plus' model differentiates it from traditional drug companies but aligns it with a broader industry trend towards holistic disease management.

More companies in Small Molecule Drugs →More companies in Germany →